Hims & Hers Health stock
Price history
−56.57% over the period1 year: from $33.62 (November 20, 2025) to $14.60 (November 20, 2026), −56.57%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | $14.60 |
| October 30, 2026 | $27.68 |
| September 30, 2026 | $29.79 |
| August 31, 2026 | $29.58 |
| July 31, 2026 | $27.77 |
| June 30, 2026 | $34.67 |
| May 29, 2026 | $26.15 |
| April 30, 2026 | $27.17 |
| March 31, 2026 | $20.76 |
| February 27, 2026 | $14.52 |
| January 30, 2026 | $27.09 |
| December 31, 2025 | $32.47 |
| November 28, 2025 | $39.76 |
| November 20, 2025 | $33.62 |
At a glance
The company
Consumer-first health and wellness platform connecting consumers to licensed healthcare professionals and offering prescription, non-prescription, and OTC products
Latest results
Quarter to September 30, 2026 · EPS -$0.14 (estimate $0.06)
TickerLandia's take on Hims & Hers Health
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−64.38% from the 52-week high
Analysts · 15 analysts
Average target$27.23+86.51% vs. price
Buy 4 · Hold 11 · Sell 0 · Hold
TickerLandia Fingerprint: Hims & Hers Health
Compared with similar companies: very weak momentum, very high risk, and very low earnings stability.
Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 888 North American stocks.
Priceaverage58
How much it costs relative to what it produces.
Metric Value Position in group Price/book 9.63 83 Forward P/E 48.7 85 Price/sales 1.19 7 Profitabilityvery low13
How much it earns on revenue and capital.
Metric Value Position in group ROA −4.0% 4 ROE −40.8% 1 Gross margin 64.8% 50 Operating margin −6.4% 4 Net margin −6.7% 4 Earnings stabilityvery low8
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 18.4% 7 Loss-making yearscounts in reverse: lower means more earnings stability 3 of 5 annual reports 9 Growthhigh64
How fast revenue and earnings are growing.
Metric Value Position in group Revenue growth (year over year) +48.60% 91 Earnings growth (year over year) −322.76% 4 Average revenue growth (3 years) +64.55% 96 Financial strengthvery low17
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Debt/equitycounts in reverse: lower means more financial strength 4.39 1 Current ratio 0.92 4 Net debt/EBITDAcounts in reverse: lower means more financial strength 5.08 1 Interest coverage 31.1 60 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumvery weak4
How the stock has moved compared with the market.
Metric Value Position in group 1-year return −56.57% 1 Distance from 200-day average −44.82% 2 Relative strength (3 months) −49.33% 1 Relative strength (6 months) −31.84% 11 Riskvery high94
How much the price swings.
Metric Value Position in group Beta (1 year) 2.64 92 Volatility (60 days) 82.2% 94 Maximum drawdown (12 months) 63.7% 96
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Hims & Hers Health is pricier than similar companies
Hims & Hers Health's Forward P/E: 48.7, +249% against the median of a group of 11 similar companies (14.0).
Compared with 11 similar companies
| Metric | Hims & Hers Health | Position in the group | Band |
|---|---|---|---|
| Forward P/E | 48.7 | High | |
| Operating margin | -6.4% | Low | |
| ROE | -40.8% | Low | |
| Debt/equity | 4.39 | High | |
| Price/book | 9.63 | High |
Grey band: the middle half of the group; tick: the median; dot: Hims & Hers Health. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$890.37M
Latest quarter · Q3 2026
Net income
-$33.04M
Latest quarter · Q3 2026
Quarterly net margin
-3.7%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- $3.42B
- EPS
- -$0.83
- Volume
- 16.06M
- Daily trading
- €322.98M
- Dividend yield
- 0.00%
How Hims & Hers Health is changing
All resultsRevenue grew 73.6% a year on average over the last 5 years
Operating margin rose from −12.6% to 5.2%
Profits turn into cash: free cash flow equal to 147% of net income
Returns
Hims & Hers Health returns
$1,000 invested in Hims & Hers Health 5 years ago, on November 22, 2021, would be worth $2,042 today: +104.20% in total, +15.37% per year. This is the price return only: dividends are excluded.
| Period | Hims & Hers Health | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | −50.02% | −10.40% | $500 |
| 6 months | −36.63% | −7.03% | $634 |
| Year to date | −55.04% | +0.95% | $450 |
| 1 year | −56.57% | +5.68% | $434 |
| 3 years | +88.63% | +51.96% | $1,886 |
| 5 years | +104.20% | +47.57% | $2,042 |
Over the last 6 months it has done better than 4% of the stocks in the Healthcare sector.
Price only, without dividends. Calculate your investment
The chart in detail
Hims & Hers Health: technical analysis
Hims & Hers Health shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 78.8% below its all-time closing high ($68.74, February 19, 2025).
- Trend
- No clear trend
- RSI (14 sessions)
- 25
- Below 30: a strong fall in a short time
- vs 200-session average
- −44.82%
Active signals
Close below the low of the previous 55 sessions.
since November 17, 2026
RSI below 30: the stock has fallen a lot in a short time.
since November 17, 2026
The last session opened more than 3% below the previous close.
Support and resistance
Price areas where Hims & Hers Health has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance$31.97+118.96%4 touches, last on October 12, 2026
- Resistance$30.26+107.28%6 touches, last on October 29, 2026
- Resistance$27.21+86.36%6 touches, last on October 15, 2026
- Last price$14.60
- No support below: the price is near the lows of the year
Volatility and risk
Over the last year it has moved more than the S&P 500.
- Beta (1 year) vs S&P 500
- 2.64
- Volatility (60 sessions, annualised)
- 82.2%
- Largest fall in the last year
- −63.72%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Hims & Hers Health: seasonality
Average monthly price change over 8 years
Over the last 8 years, the strongest month for Hims & Hers Health has been November: +18.79% on average, positive in 5 years out of 7. The weakest has been August: −11.60% on average, positive in 3 years out of 7.
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +9.90% | +1.52% | 4 of 7 |
| February | +6.60% | +6.97% | 4 of 7 |
| March | +1.10% | −0.38% | 3 of 7 |
| April | +1.85% | −0.30% | 3 of 7 |
| May | +15.89% | −0.37% | 3 of 7 |
| June | +2.85% | +3.96% | 5 of 7 |
| July | +3.43% | +1.28% | 4 of 7 |
| August | −11.60% | −0.38% | 3 of 7 |
| September | +7.00% | +0.71% | 4 of 7 |
| October | −7.30% | −6.01% | 2 of 8 |
| November | +18.79% | +3.14% | 5 of 7 |
| December | −0.15% | 0.00% | 3 of 7 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Hims & Hers Health and its competitors
Based in San Francisco, California, Hims & Hers Health, Inc. has existed since 2017 as a consumer health and wellness platform that links customers with licensed healthcare professionals. Prescription and non-prescription products are sold through its websites, mobile application, retail partners and stores, alongside medical consultations and laboratory testing. Under the Hims & Hers brand, it offers over-the-counter drugs, devices, cosmetics and supplements for skincare, sexual health, hair care and general wellness, plus treatments for chronic conditions in hormone health, weight loss, dermatology and mental health.
- Headquarters
- San Francisco, United States
- Employees
- 2,442
- Founded
- 2017
- Chief executive
- Andrew Dudum
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Hims & Hers HealthHIMS | $3.42B | -6.4% | — | −36.63% |
| Neurocrine BiosciencesNBIX | $15.24B | 26.6% | 22.3 | −2.65% |
| ViatrisVTRS | $22.5B | 11.5% | — | +18.32% |
| United TherapeuticsUTHR | $23.63B | 39.4% | 20.9 | −1.63% |
| ZoetisZTS | $32.14B | 37.9% | 13.5 | −0.75% |
| Teva Pharmaceutical IndustriesTEVA | $45.77B | 19.8% | 91.2 | +14.31% |
Same industry or related industries, similar size. Compare Hims & Hers Health with its competitors · Full profile
